July 31, 2019
Mark Saxton has been appointed NeuroPace Vice President of Sales.
Mark Saxton is an accomplished medical device industry executive and drove the successful commercialization of multiple transformational technologies while holding a variety of sales and marketing roles over the last 25 years.
Prior to joining NeuroPace, Mark Saxton served as Vice President of Sales and Marketing for Ceterix Orthopaedics, the manufacturer of a novel meniscal repair system which was acquired by Smith & Nephew in 2018. Previously, Mr. Saxton served as Vice President of Product Solutions for Integer, a global healthcare leader dedicated to creating innovative medical technologies to enhance patients’ lives. His experience at Integer followed multiple positions of increasing responsibility, including his role as Vice President of Sales and Customer Service at VNUS Medical, which pioneered the minimally invasive treatment of venous reflux disease and was acquired by Medtronic.
“Mark Saxton’s expertise in advancing medical technologies will be a tremendous asset to NeuroPace as the company prepares for the next phase of growth in the coming year,” said NeuroPace CEO Mike Favet. “We are thrilled to welcome Mark to the team at this exciting time for our company. His knowledge and impressive track record will help us achieve our mission to improve the lives of patients and families living with epilepsy.”
“I am excited to join NeuroPace and further the company’s vision of leveraging groundbreaking technology to provide personalized treatment options to those living with refractory epilepsy,” said Mr. Saxton. “NeuroPace’s technology is a life-changing therapy for drug-resistant focal epilepsy, and I look forward to expanding patient and physician access to this important treatment option.”
The company’s RNS® System is the only device that monitors and responds to a patient’s unique brain patterns to deliver therapy that can stop seizures within milliseconds of detecting abnormal brain activity – even before symptoms occur.